First year after market approval, ICE Intelligent Healthcare secures ~￥100M in Series Funding

Recently, ICE Intelligent Healthcare, the industry's first fully self-developed intelligent interventional ultrasound imaging platform company, announced the completion of a tens of millions Series A+ funding round. This round was led by BOCI. The raised funds will primarily be used for the construction and operation of production facilities, as well as supplementing working capital. This investment represents another round of financing secured by ICE Intelligent Healthcare within a short period, bringing the total funding from the two rounds to nearly 100 million.

Established in 2021, ICE Intelligent Healthcare has built a strong core team with members from leading industry players such as GE, Johnson & Johnson, Siemens, Abbott, and SonoScape. Their professional backgrounds comprehensively cover interventional cardiology, imaging, consumables, artificial intelligence, and related fields. The multidisciplinary expertise of the core team in medicine, engineering, and business has not only enabled ICE Intelligent Healthcare to efficiently develop integrated product pipelines but also made it the only company in the industry to achieve full-chain independent R&D and cost control across the interventional ultrasound imaging chain—from transducers, probes, and consoles to image processing and AI algorithms.

ICE Intelligent Healthcare positions itself as an "intelligent interventional ultrasound technology platform company." With intracardiac echocardiography (ICE) as its core focus, ICE Intelligent Healthcare is comprehensively expanding into other specialized interventional ultrasound fields, including gastrointestinal, tracheal, coronary, and peripheral interventional ultrasound. In the intracardiac echocardiography domain, ICE Intelligent Healthcare has launched multiple products such as 2D ICE, HD ICE, 3D ICE, and 4D ICE, making it the company with the most comprehensive pipeline in interventional ultrasound.

ICE Intelligent Healthcare's 2D ICE product received regulatory approval in February 2025 and has since participated in centralized procurement processes across various regions. This marks ICE Intelligent Healthcare's first product to obtain a Class III medical device registration certificate. Thanks to its superior image quality, the product has gained widespread recognition from medical experts. During the 2025 centralized procurement in Sichuan, it became the most widely adopted China-developed product in hospitals. Additionally, ICE Intelligent Healthcare's product successfully secured a place in the 2025 Beijing centralized procurement.

Furthermore, ICE Intelligent Healthcare's 2D ICE product has collaborated with top-tier hospitals in China, including Beijing Anzhen Hospital, Fuwai Hospital, and Shanghai Zhongshan Hospital, to conduct over 120 human clinical trials. Clinical data demonstrate that the 2D ICE product delivers outstanding performance in imaging quality and resolution.

Beyond 2D ICE, ICE Intelligent Healthcare has also made significant progress in other intracardiac echocardiography products. For instance, in the development of 4D ICE, the company focuses on the internationally mainstream ultra-high channel count electronic matrix transducer technology, rather than 3D reconstruction-based simulation of 4D technology. It has already completed the prototyping of a commercial-grade transducer with 896 channels. This transducer is independently manufactured end-to-end by ICE Intelligent Healthcare, achieving a 100% yield rate across three production batches. Notably, ICE Intelligent Healthcare's electronic matrix 4D ICE product adopts a fully new proprietary technical approach, which not only breaks the international monopoly on ASIC chips but also significantly reduces the cost of 4D ICE usage.

Looking ahead, with the continuous growth in electrophysiology procedures, the increasing adoption of pulsed-field ablation (PFA) as a mainstream electrophysiology technique, and the growing consensus on the integration of PFA and ICE, the application scope and market potential of ICE are expected to expand further. As domestic Chinese companies like ICE Intelligent Healthcare lead the way in breaking import monopolies, local manufacturers are poised to continue driving innovation in this market and reshaping its competitive landscape.

Moving forward, ICE Intelligent Healthcare will continue to build on its fully self-developed and self-manufactured ultrasound imaging chain by further strengthening AI technology R&D. ICE Intelligent Healthcare is committed to launching innovative products and services that address real clinical needs, effectively tackling challenges in clinical practice. Simultaneously, ICE Intelligent Healthcare aims to evolve into a specialized digital cardiac acoustic imaging company that provides comprehensive pre-operative, intra-operative, and post-operative solutions, empowering the entire workflow of cardiac disease diagnosis and treatment with digital and intelligent technologies.